Skip to main content
ScholarsBetaWeill Cornell Medicine

Highlights

  1. 1
    European journal of nuclear medicine and molecular imaging · 2018
    JKJames Kelly
    PMID: 29623376DOIFirst author84 citations
  2. 2
    EJNMMI radiopharmacy and chemistry · 2021
    JKJames Kelly
    PMID: 34928478PMCID: PMC8688611DOIFirst author26 citations
  3. 3
    Translational oncology · 2022
    JKJames Kelly
    PMID: 35597190PMCID: PMC9123266DOISenior author53 citations

Publications

40 publications

Funding

13 grantsView NIH portfolio on RePORTER ↗

Active

6 grants
  • Co-I
    Dual-[Hypoxia+Proliferation] PET as a Predictive Biomarker in Recurrent Glioblastoma
    National Cancer Institute · 2026–2031
    R01CA308323-01A1
  • KP
    Modernization and Expansion of the Citigroup Biomedical Imaging Center at Weill Cornell Medical College
    Office of the Director, NIH · 2023–2027
    C06OD036045-01
  • Co-I
    Clinical and Translational Science Center- Institutional CTSC Internal Funding UL1
    CTSC Cost Share · 2022–2027
    UL1TR002384-06
  • Co-I
    Development and optimization of CEACAM5-targeted alpha emitters
    Prostate Cancer Foundation · 2025–2027
    24CHAL11
  • PI
    Investigating PK modulation in targeted radiotherapy
    Ratio Therapeutics, LLC · 2022–2026Contract
    SRA 224196-04
  • KP
    New PET/CT System for Human and Non-human Primate Imaging
    Office of the Director, NIH · 2023–2026
    S10OD034271-01
Completed grants (7)
  • KP
    Imaging Incipient Heart Failure by PET
    National Heart, Lung, and Blood Institute · 2023–2025Fellowship
    F32HL168948-01
  • Co-I
    CSF Clearance in Sporadic Alzheimer's Disease
    National Institute on Aging · 2019–2025
    R01AG057848-02
  • PI
    The Development of Radiolabeled Positional isomers of [11C]Pyruvate for Imaging Cancer Metabolism
    National Institute of Biomedical Imaging and Bioengineering · 2020–2024
    R21EB029649-03
  • Co-I
    Targeting lipid metabolism and diet in patients with locally advanced prostate cancer
    Prostate Cancer Foundation · 2023–2023
    PCF 227920-01
  • KP
    Major Cyclotron Upgrades and Refurbishment
    Office of the Director, NIH · 2021–2023
    S10OD030447-01
  • PI
    PET Imaging Biomarkers to Predict Cardiac Remodeling and Functional Decline in Cardiotoxicity Arising from Chemotherapy
    National Cancer Institute · 2019–2022
    R21CA246409-02
  • Co-I
    Radiolabeled FASN Inhibitors for PET Imaging
    National Cancer Institute · 2016–2019
    R21CA213157-02

Clinical research

1 study

Active

1 study
  • PI
    Salivary Transglutaminase Activity
    Weill Medical College of Cornell University · OPEN TO ACCRUAL (as of 2025)

Available technologies

2 technologiesView full WCM portfolio ↗

News mentions

1 mentionView all WCM news ↗
  • Machine Learning: Can 3D Printing Make Nuclear Medicine More Accessible Worldwide?
    March 24, 2021

    Medicines that contain radioactive isotopes—known as radiopharmaceuticals—are used to treat cancer and to help physicians diagnose a wide variety of conditions through imaging. But while radiopharmaceuticals are a standard and invaluable medical tool in the field of nuclear medicine, synthesizing them can be challenging.

Mentoring

6 menteesAll publications with mentees →

External relationships

Ownership

Ratio Therapeutics, LLC

Proprietary Interest

Bayer, A.G. (Germany) · Ratio Therapeutics, LLC